Navigation Links
Updated Phase 1 Data for Exelixis' XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
Date:10/23/2007

atients received two cycles of XL184 administered as a daily oral dose for 5 consecutive days with a 9-day observation period (0.08-11.52 mg/kg), or dosed daily (175 and 265 mg). Patients may remain on study in the absence of unacceptable toxicity or progressive disease. Primary endpoints of the trial are to evaluate the safety and tolerability of XL184, determine the MTD of XL184, and to evaluate the plasma pharmacokinetics of XL184 administered orally to patients with advanced malignancies. Secondary endpoints are to assess the preliminary anti-tumor activity after repeat administration of XL184, and to assess the effects of XL184 on vascular permeability in patients enrolled at the MTD. An evaluation of the pharmacodynamic effects of XL184 is being conducted as an exploratory endpoint.

About XL184

XL184 is a novel, orally administered, small molecule anticancer compound that in preclinical models has demonstrated potent inhibition of both MET and VEGFR2. XL184 has also exhibited potent inhibition of other important receptor tyrosine kinases (RTKs) that have been implicated in various forms of cancer including RET, KIT, FLT3, and TIE2. In preclinical efficacy studies, XL184 has inhibited tumor growth and induced the regression of large tumors in a broad range of human tumor xenograft models including breast cancer, lung cancer and glioma. In laboratory studies, XL184 has demonstrated good oral bioavailability and pharmacokinetic properties.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and ren
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
6. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
7. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
8. Media Advisory: ACC Updated Schedule
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Reaching a critical milestone in the ... of Boards of Pharmacy ® (NABP ® ) ... has passed the Internet Corporation for Assigned Names and ... .PHARMACY gTLD by the end of 2013, and will ... and related entities that are located in ...
(Date:5/21/2013)... 21, 2013 Valeant Pharmaceuticals ... ) (TSX: VRX) today announced the ... its 2013 annual meeting of shareholders ... vote for the election of directors ... Farmer235,731,9341,964,748Robert A. Ingram233,865,8763,830,806Theo Melas-Kyriazi237,081,508615,174G. Mason Morfit235,623,2832,073,399J. ...
(Date:5/21/2013)... de 2013 La junta directiva de ... OMNIlife science®, Inc., Enztec, Ltd. y Praxim, SA, han ... Mayer, un ejecutivo ortopédico experimentado, será vicepresidente de ... , un experto refutado en dispositivos médicos, ... unirse a OSI como presidente de la junta, ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Valeant Pharmaceuticals Announces 2013 Annual Meeting Results 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 2Orthopaedic Synergy, Inc. anuncia nuevas incorporaciones a la junta directiva 3
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:5/21/2013)... Mecklenburg EMS Agency (Medic) and the ... Community Wellness Fair to educate the public on health initiatives ... on Wednesday, May 22, 2013 from 4:00 pm until 7:00 ... Mallard Creek Road, Charlotte, NC 29262). , Medic, ... Mecklenburg County Department of Social Services are working ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... 2013 According to a May 13, 2013 ... of Botox,” Botox injections have become the most ... 2002 (Go to goo.gl/8iYbD). Although it is mostly associated with ... The injection makes facial wrinkles less visible by paralyzing facial ... about three months. This means that people who are conscious ...
(Date:5/21/2013)... Hillsboro, OR (PRWEB) May 21, 2013 ... curing systems at the 20th Annual IMI European ... As a proven market leader, Phoseon continues to invest ... while accelerating the adoption of UV LED curing in ... of product families on the market offering both air ...
(Date:5/21/2013)... May 21, 2013 MedMar Healing Center ... to benefit Second Harvest Food Bank. Twenty-eight businesses, including MedMar ... in the food drive. The goal is to raise food ... economic problems facing their families in recent years. , ... and help those in need,” explains Douglas Chloupek of MedMar ...
Breaking Medicine News(10 mins):Health News:Mecklenburg EMS Agency Teams Up with the YMCA of Greater Charlotte and Others to Educate the Public on Health Related Initiatives 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:San Jose Cannabis Club Helps Feed Hungry Children with Second Harvest Food Bank 2
... 4 Formerly conjoined twins,Yurelia and Fiorella Rocha-Arias ... are now home in Costa Rica. According to ... (30) and went,to Southern California to visit Mending ... trip. Today (4), they flew home,to San Jose, ...
... (Nasdaq: MLNM ) today announced that its ... will be webcast live and may be,accessed by ... http://www.millennium.com ., (Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO ), ... the Company, VELCADE(R),(bortezomib) for Injection, other product candidates ...
... attractions when swallowed by kids, new report shows. , , MONDAY, ... a little boy who swallowed a magnet and wound up ... Jose, Calif., swallowed two tiny magnets from his older brother,s ... the first ingestion, he confessed to his mom, Jill Eberle, ...
... budget for fiscal year 2009, if enacted, would spell ... national effort to respond to the HIV/AIDS epidemic in ... flat-funds critical federal support for research at the National ... Centers for Disease Control and Prevention (CDC), and vital ...
... ... and Commit(R), PITTSBURGH, Feb. 4 GlaxoSmithKline ... cessation products in January 2008, which includes NicoDerm CQ,patches, Nicorette gum, and ... try and quit, unfortunately, many of them fail,without the proper tools and ...
... Costs, WASHINGTON, Feb. 4 The Pharmaceutical ... response to,the Federal Trade Commission,s (FTC) recent opposition ... corporate health care providers in,Puerto Rico to collectively ... comment from the FTC highlights the agency,s consistent,opposition ...
Cached Medicine News:Health News:Formerly Conjoined Twins Leave Packard Children's Hospital; Heading Home to Costa Rica 2Health News:BIO CEO & Investor 2008 Conference to Webcast Millennium Presentation 2Health News:Toy Magnets Can be a Very Real Threat 2Health News:Toy Magnets Can be a Very Real Threat 3Health News:2009 Bush budget a disaster for HIV/AIDS 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 2Health News:One Million Boxes of Over-the-Counter Smoking Cessation Products Sold in January 2008 3
5 mm concave jaws, cross action....
... inserter is the first of its kind. ... through a minimal incision. The special direct-acting ... bag with complete control and predictability. The ... easy around-the-clock, and the instrument has a ...
... SI-30 and SI-40 foldable lenses through incisions as ... clear corneal and corneal scleral tunnels. The inserter ... rounded blades for a secure grasp of a ... a .15 millimeter notch which may be used ...
KR-8000 Supra is capable of obtaining perfectly accurate keratometry and/or refraction measurements through pupils as narrow as 2.0 mm....
Medicine Products: